Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy

  • Authors:
    • S. Sato
    • A. Yajima
    • H. Sasaki
    • K. Mizutani
    • H. Honjo
    • K. Yamamoto
    • M. Ozaki
    • K. Hasegawa
    • T. Kudo
    • M. Yakushiji
    • M. Hatae
    • K. Noda
  • View Affiliations

  • Published online on: March 1, 2001     https://doi.org/10.3892/or.8.2.239
  • Pages: 239-244
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Thymidine phosphorylase (dThdPase) is reportedly identical to platelet-derived endothelial cell growth factor (PD-ECGF). We conducted immunohistochemical staining of dThdPase to assess correlation between its expression in cancer tissue and efficacy of a combination therapy with 5'-DFUR, radiotherapy and sizofilan (SPG) in uterine cervical cancer patients. No difference in response rates was observed between dThdPase positive and negative tumor and stromal cells. Survival curves significantly differed between stromal dThdPase positive and negative groups (p=0.032). Results showed that dThdPase immunostaining is possibly prognostic and predictive in determining success of the combination therapy.

Related Articles

Journal Cover

March-April 2001
Volume 8 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sato S, Yajima A, Sasaki H, Mizutani K, Honjo H, Yamamoto K, Ozaki M, Hasegawa K, Kudo T, Yakushiji M, Yakushiji M, et al: Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy. Oncol Rep 8: 239-244, 2001
APA
Sato, S., Yajima, A., Sasaki, H., Mizutani, K., Honjo, H., Yamamoto, K. ... Noda, K. (2001). Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy. Oncology Reports, 8, 239-244. https://doi.org/10.3892/or.8.2.239
MLA
Sato, S., Yajima, A., Sasaki, H., Mizutani, K., Honjo, H., Yamamoto, K., Ozaki, M., Hasegawa, K., Kudo, T., Yakushiji, M., Hatae, M., Noda, K."Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy". Oncology Reports 8.2 (2001): 239-244.
Chicago
Sato, S., Yajima, A., Sasaki, H., Mizutani, K., Honjo, H., Yamamoto, K., Ozaki, M., Hasegawa, K., Kudo, T., Yakushiji, M., Hatae, M., Noda, K."Prognostic value of thymidine phosphorylase immunostaining in patients with uterine cervical cancer treated concurrently with doxifluridine, radiotherapy and immunotherapy". Oncology Reports 8, no. 2 (2001): 239-244. https://doi.org/10.3892/or.8.2.239